nivolumab,ipilimumab,Niraparib,Balstilimab,Botensilimab
bms,gsk,Agenus
[]
 &amp; others have shown that not all immunotherapies are alike. pd1 parp very different ctla4 combinations. ongoing #botbal studies are also evaluating if the bal is necessary and what dose of bot. t300 d single dose continues to intrigues me. #gi23 
Oncologist | Researcher | ColorectalCancer #CRCSM👨🏼‍🎓@MayoClinic @PittTweet Alum; 🧬#ctDNA #LiquidBiopsies💡#PrecisionOncology ViewsMy Own. COI @ASCO📍 #GI23